2006
DOI: 10.1007/s10555-006-7894-9
|View full text |Cite
|
Sign up to set email alerts
|

Recent advances in MMP inhibitor design

Abstract: The search for an MMP inhibitor with anticancer efficacy is a nearly three-decade endeavor. This inhibitor is yet to be found. The reasons for this failure include shortcomings in the chemistry of these compounds (including broad MMP sub-type selectivity, metabolic lability, and toxicity) as well as the emerging, and arguably extraordinary, complexity of MMP cell (and cancer) biology. Together these suggest that the successful anticancer inhibitor must possess MMP selectivity against the MMP subtype whose invo… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

2
206
0
1

Year Published

2007
2007
2015
2015

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 239 publications
(209 citation statements)
references
References 217 publications
(217 reference statements)
2
206
0
1
Order By: Relevance
“…Anti-angiogenesis and blockers of enzymes involved in cancer cell-matrix interactions are currently under clinical investigation 97,98 with important benefits already obtained in randomised trials. 99 The tumor-associated fibroblast, has only recently became the focus of attention as an eventual anti-neoplasic therapeutic target.…”
Section: Therapeutic Implicationsmentioning
confidence: 99%
“…Anti-angiogenesis and blockers of enzymes involved in cancer cell-matrix interactions are currently under clinical investigation 97,98 with important benefits already obtained in randomised trials. 99 The tumor-associated fibroblast, has only recently became the focus of attention as an eventual anti-neoplasic therapeutic target.…”
Section: Therapeutic Implicationsmentioning
confidence: 99%
“…One obstacle to experimentally address distinct functions of gelatinases in vivo is that their structural similarity in the vicinity of the active center impedes the design of synthetic inhibitors targeting specifically only one gelatinase (20,21).…”
Section: Introductionmentioning
confidence: 99%
“…Through this effort we identified compound 2, a tetrahydropyran-based hydroxamate, which is a derivative of a known inhibitor (RS-130830) of matrix metalloprotease (MMP)-2, -8, -9, and -13. 19 Tetrahydropyran-based compound 2 demonstrated potent inhibition of P. aeruginosa LpxC (7.4 nM, Table 1), moderate cellular activity against P. aeruginosa PAO1 (MIC = 50 μM), but poor activity against wild-type Escherichia coli (E. coli ARC523 MIC >200 μM). We were attracted to the tetrahydropyran since this structural motif had not been employed in other LpxC inhibitors, yet it has similarity when compared to the natural substrate, UDP-3-O-(acyl)-N-acetylglucosamine.…”
mentioning
confidence: 99%